|Mr. Dilip Shantilal Shanghvi||MD & Exec. Director||31.8M||N/A||1955|
|Mr. Sailesh T. Desai||Whole Time Director||13.9M||N/A||1954|
|Mr. Sudhir Vrundavandas Valia||Whole Time Director||31.58M||N/A||1956|
|Mr. Kalyanasundaram Subramanian||CEO of India Bus. & Emerging Markets and Exec. Non-Independent Director||N/A||N/A||1954|
|Mr. Sunil R. Ajmera||Company Sec.||11.75M||N/A||N/A|
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental, and nutritionals. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products. The company has a collaboration agreement with International Centre for Genetic Engineering and Biotechnology to develop Dengue vaccine. Sun Pharmaceutical Industries Limited was founded in 1983 and is based in Mumbai, India.
Sun Pharmaceutical Industries Limited’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 1; Compensation: 7.